Milsaperidone Patent Expiration
Milsaperidone was first introduced by Vanda Pharmaceuticals Inc
Milsaperidone Patents
Given below is the list of patents protecting Milsaperidone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bysanti | US12478619 | Method Of Treatment With Milsaperidone | May 31, 2044 | Vanda Pharms Inc |
| Bysanti | US9074254 | Method of predicting a predisposition to QT prolongation | Dec 28, 2031 | Vanda Pharms Inc |
| Bysanti | US9074256 | Method of predicting a predisposition to QT prolongation | Feb 10, 2031 | Vanda Pharms Inc |
| Bysanti | US9072742 | Method of predicting a predisposition to QT prolongation | Jan 16, 2031 | Vanda Pharms Inc |
| Bysanti | US9074255 | Method of predicting a predisposition to QT prolongation | Dec 17, 2030 | Vanda Pharms Inc |
| Bysanti | US8999638 | Method of treatment based on polymorphisms of the KCNQ1 gene | Oct 28, 2030 | Vanda Pharms Inc |
| Bysanti | US10563259 | Method Of Treatment Based On Polymorphisms Of The Kcnq1 Gene | Jul 24, 2030 | Vanda Pharms Inc |
| Bysanti | US9157121 | Method of treatment based on polymorphisms of the KCNQ1 gene | Apr 05, 2030 | Vanda Pharms Inc |
| Bysanti | US10570453 | Method Of Predicting A Predisposition To Qt Prolongation | Mar 28, 2028 | Vanda Pharms Inc |
Milsaperidone's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List